Status:
COMPLETED
Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.
Lead Sponsor:
Laval University
Conditions:
Human Papillomavirus
Eligibility:
FEMALE
12-14 years
Phase:
PHASE3
Brief Summary
Two human papillomavirus vaccines are now commercially available. No clinical data exist regarding: * The immunogenicity and safety of Gardasil and Twinrix when co-administered. * The immunogenicity...
Eligibility Criteria
Inclusion
- In 2008-2009 received two doses of Gardasil at the age of 9-10 years according to 0, 6 months schedule.
Exclusion
- Received less than two doses of Gardasil or received an HPV vaccine outside the study protocol.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
418 Patients enrolled
Trial Details
Trial ID
NCT01456715
Start Date
September 1 2008
End Date
December 1 2018
Last Update
March 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laval University Research Hospital Center
Québec, Canada, G1E7G9